Logo image of SVRA

SAVARA INC (SVRA) Stock Fundamental Analysis

NASDAQ:SVRA - Nasdaq - US8051111016 - Common Stock - Currency: USD

2.4  +0.12 (+5.26%)

After market: 2.4 0 (0%)

Fundamental Rating

2

Overall SVRA gets a fundamental rating of 2 out of 10. We evaluated SVRA against 558 industry peers in the Biotechnology industry. The financial health of SVRA is average, but there are quite some concerns on its profitability. SVRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SVRA had negative earnings in the past year.
SVRA had a negative operating cash flow in the past year.
SVRA had negative earnings in each of the past 5 years.
In the past 5 years SVRA always reported negative operating cash flow.
SVRA Yearly Net Income VS EBIT VS OCF VS FCFSVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

SVRA's Return On Assets of -53.97% is in line compared to the rest of the industry. SVRA outperforms 47.13% of its industry peers.
The Return On Equity of SVRA (-69.11%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -53.97%
ROE -69.11%
ROIC N/A
ROA(3y)-27.48%
ROA(5y)-38.13%
ROE(3y)-34.71%
ROE(5y)-51.61%
ROIC(3y)N/A
ROIC(5y)N/A
SVRA Yearly ROA, ROE, ROICSVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SVRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SVRA Yearly Profit, Operating, Gross MarginsSVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for SVRA has been increased compared to 1 year ago.
Compared to 5 years ago, SVRA has more shares outstanding
The debt/assets ratio for SVRA has been reduced compared to a year ago.
SVRA Yearly Shares OutstandingSVRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
SVRA Yearly Total Debt VS Total AssetsSVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of 1.03, we must say that SVRA is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.03, SVRA is doing good in the industry, outperforming 67.92% of the companies in the same industry.
A Debt/Equity ratio of 0.20 indicates that SVRA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.20, SVRA is doing worse than 70.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 1.03
ROIC/WACCN/A
WACCN/A
SVRA Yearly LT Debt VS Equity VS FCFSVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 14.91 indicates that SVRA has no problem at all paying its short term obligations.
SVRA has a better Current ratio (14.91) than 87.99% of its industry peers.
A Quick Ratio of 14.91 indicates that SVRA has no problem at all paying its short term obligations.
The Quick ratio of SVRA (14.91) is better than 87.99% of its industry peers.
Industry RankSector Rank
Current Ratio 14.91
Quick Ratio 14.91
SVRA Yearly Current Assets VS Current LiabilitesSVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SVRA have decreased strongly by -29.73% in the last year.
EPS 1Y (TTM)-29.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SVRA will show a very strong growth in Earnings Per Share. The EPS will grow by 21.13% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-47.82%
EPS Next 2Y-25.94%
EPS Next 3Y-8.98%
EPS Next 5Y21.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SVRA Yearly Revenue VS EstimatesSVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2020 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SVRA Yearly EPS VS EstimatesSVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SVRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SVRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SVRA Price Earnings VS Forward Price EarningsSVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SVRA Per share dataSVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

SVRA's earnings are expected to decrease with -8.98% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.94%
EPS Next 3Y-8.98%

More info and screens

0

5. Dividend

5.1 Amount

SVRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAVARA INC

NASDAQ:SVRA (6/2/2025, 8:00:01 PM)

After market: 2.4 0 (0%)

2.4

+0.12 (+5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners91.02%
Inst Owner Change0.07%
Ins Owners2.32%
Ins Owner Change2.56%
Market Cap414.82M
Analysts84.29
Price Target9.63 (301.25%)
Short Float %11.09%
Short Ratio16.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.99%
Min EPS beat(2)-14.48%
Max EPS beat(2)8.5%
EPS beat(4)2
Avg EPS beat(4)-3.53%
Min EPS beat(4)-14.48%
Max EPS beat(4)8.5%
EPS beat(8)4
Avg EPS beat(8)-4.42%
EPS beat(12)7
Avg EPS beat(12)-2.31%
EPS beat(16)10
Avg EPS beat(16)4.35%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.31%
EPS NQ rev (1m)1.56%
EPS NQ rev (3m)-19.18%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.81
P/tB 3.03
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS0.86
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.97%
ROE -69.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.48%
ROA(5y)-38.13%
ROE(3y)-34.71%
ROE(5y)-51.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.91
Quick Ratio 14.91
Altman-Z 1.03
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)153.1%
Cap/Depr(5y)347.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y-47.82%
EPS Next 2Y-25.94%
EPS Next 3Y-8.98%
EPS Next 5Y21.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-55.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.99%
EBIT Next 3Y27.97%
EBIT Next 5YN/A
FCF growth 1Y-145.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-145.78%
OCF growth 3YN/A
OCF growth 5YN/A